Results 91 to 100 of about 2,929 (206)

Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System

Therapeutic Advances in Drug Safety
Background: Prolonged or excessive use of acid suppressants may increase the risk of Clostridioides difficile infection (CDI) by altering the intestinal microecosystem.
Mengling Ouyang, Shupeng Zou, Qian Cheng, Xuan Shi, Yazheng Zhao, Minghui Sun   +5 more
doaj   +1 more source

Approach to esophageal absent contractility: can we do better? [PDF]

Absent contractility (AC), a motility disorder characterized by the absence of esophageal contractions while maintaining normal lower esophageal sphincter relaxation, is recognized as a distinctive major disorder of peristalsis on esophageal high ...
Abboud W., Baker F. A., Cohen D. L., Cohen S., Khoury T., Mari A., Pesce M., Savarino E. V.   +7 more
core   +1 more source

A systematic review with meta‐analysis: Efficacy and safety of potassium‐competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis

JGH Open
Introduction Proton pump inhibitor (PPI) is the mainstay therapy for the maintenance of healed erosive esophagitis (EE). It is unknown whether potassium‐competitive acid blockers (PCABs) are more efficacious and safer than PPIs.
Daniel M Simadibrata, Elvira Lesmana, Muhammad I A Pratama, Adrianus J Sugiharta, Afiah S Winarizal, Yeong Y Lee, Ari F Syam   +6 more
doaj   +1 more source

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis

Therapeutic Advances in Gastroenterology, 2017
Background: Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors (PPIs), but some patients are resistant to PPIs.
Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Kentaro Kudou, Akira Nishimura, Naoki Hiramatsu, Eiji Umegaki, Kiyoshi Ashida   +8 more
doaj   +1 more source

Examination on factors affecting symptom change after drug withdrawal in patients with mild erosive gastroesophageal reflux disease undergoing symptom-controlled maintenance therapy with acid-secretion inhibition drugs [PDF]

, 2023
大阪医科薬科大学博士（医学 ...
1596, タナカ, ヒロノリ, 田中, 宏典   +2 more
core  

Efficacy of Vonoprazan 10 mg and 20 mg for Patients With Proton Pump Inhibitor‐Refractory Functional Dyspepsia: A Double‐Blinded, Randomized Study

JGH Open
Background A proportion of patients with functional dyspepsia (FD) have inadequate symptom control with proton pump inhibitors (PPIs) treatment. Vonoprazan demonstrates higher efficacy in acid reduction than PPI; however, the existing efficacy data for ...
Chalermrat Bunchorntavakul, Pantaree Jaigla   +1 more
doaj   +1 more source

Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial [PDF]

, 2020
横浜市立大学2019年
土谷 一泉
core   +1 more source

Widespread use of proton pump inhibitors or potassium-competitive acid blocker has changed the status of gastrointestinal bleeding in patients with ischemic heart disease: real-world data from high volume centers [PDF]

大阪医科薬科大学博士（医学）2024doctoral ...
ササキ, シュン, 佐々木, 駿
core   +1 more source

Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers. [PDF]

Zastaprazan (JP-1366) is a novel potassium-competitive acid blocker for the treatment of acid-related disorders. We aimed to establish a population pharmacokinetic (PK) model of zastaprazan, thereby characterizing the PK of zastaprazan in patients with ...
Hwang, Inyoung, Ji, Sang, Kim, John, Lee, SeungHwan, Yang, Eunsol   +4 more
core   +1 more source

Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis

Pharmaceuticals
Novel potassium-competitive acid blockers (P-CABs) have emerged as effective acid-suppressive drugs in recent years, replacing proton pump inhibitors (PPIs).
Mengling Ouyang, Shupeng Zou, Qian Cheng, Xuan Shi, Yazheng Zhao, Minghui Sun   +5 more
doaj   +1 more source